Solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC) and nanoemulsion (NE) of lornoxicam (LRX) were prepared for the treatment of painful and inflammatory conditions of the skin. Compritol ® 888 ATO, Lanette ® O and oleic acid were used as solid and liquid lipids. SLN, NLC and NE were found physically stable at various temperatures for 6 months. Case I diffusional drug release was detected as the dominant mechanism indicating Fickian drug diffusion from nanoparticles and nanoemulsion. The highest rate of drug penetration through rat skin was obtained with NE followed by NLC, SLN and a gel formulation. Nanoformulations significantly increased drug penetration through rat skin compared to the gel (p < 0.05). Thus, SLN, NLC and NE of LRX can be suggested for relieving painful and inflammatory conditions of the skin.
Topical application of NSAIDs can be an alternative route to overcome the GI side eff ects of NSAIDs, including LRX (3, 4) . Nanoparticles based on lipophilic materials like waxes or fats appear to be a ractive colloidal carrier systems for the delivery of drugs through distinct routes, including topical application (5, 6) . They have several advantages over traditional delivery systems. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) display their unique benefi ts in drug delivery and various desirable eff ects on the skin. They have a moisturizing eff ect on the skin through occlusion providing an increase in skin hydration (7) . They are well suited for use on damaged or infl amed skin since they are based on non-irritant and non-toxic lipids. Several studies report successful incorporation of active compounds into SLN and NLC, and their related benefi ts as colloidal carrier systems are described in the literature (8) (9) (10) (11) . Nanoemulsion (NE) is also a good candidate for skin delivery of drugs.
Both placebo and LRX-loaded SLN/NLC/NE formulations were a empted to be produced by the hot high pressure homogenization technique. Physical stability experiments on formulations were carried out. Drug penetration through full-thickness skins of rats was studied. A LRX gel was also prepared for comparison with SLN, NLC and NE in in vitro and ex vivo experiments.
EXPERIMENTAL

Materials
Lornoxicam was gratefully obtained from Abdi İbrahim İlaç Sanayi ve Tic. A.Ş. (Turkey). Compritol ® 888 ATO and Lane e ® O were kindly provided by B'IOTA Laboratories (Turkey). Pluronic ® F68 and oleic acid were purchased from Sigma-Aldrich (Turkey) and Merck (Germany), respectively. Xanthan gum (Inner Mongolia Jianlong Biochemical Co., Ltd, China) was obtained as a gi . All other chemicals were of analytical grade.
Preparation of SLN, NLC and NE
Placebo SLN formulations (PSLN1 and PSLN2) were prepared by the high pressure homogenization technique at 90 o C (Table I ) (12) . Hot aqueous surfactant solution was poured into melted lipid and stirred with an UltraTurrax (IKA, Germany) at 20,000 rpm for 1 minute. The coarse emulsion obtained was homogenized using a double-stage APV-2000 high pressure homogenizer (SPX Flow Technology, Poland) at 5 × 10 6 and 15 × 10 7 Pa for the fi rst and second stage, respectively. Three homogenization cycles were employed. Hot pre-emulsion was poured into silanized transparent vials and sealed. Vials were immediately cooled down to 25 °C for formation of nanoparticles. LRX was incorporated into the lipophilic phase for preparation of SLN1 and SLN2.
Placebo NLC (PNLC1 and PNLC2) and LRX loaded -NLC formulations (NLC1 and NLC2) were prepared by the same technique under the same conditions. Oleic acid was used by reducing the fraction of Compritol ® 888 ATO and Lane e ® O to produce PNLC1 and PNLC2, respectively (i.e. the total lipid content remained unchanged) as can be seen in Table I . 2 % LRX of the total formulation was added by reducing the solid lipid amount in the production of NLC1 and NLC2.
Placebo and LRX loaded NE (PNE and NE) were produced by completely replacing the solid lipid in SLN formulations with oleic acid using the same production process for comparison (Table I) . All vials were then stored at 4, 25 and 40 o C in the dark in order to determine their physical stability over 6 months.
A LRX gel, as a traditional topical dosage form, was also prepared to evaluate the drug release characteristics and skin penetration behaviour of SLN, NLC and NE through the skin by comparison. For this purpose, xanthan gum was added to the total water content of the gel formulation (Table I ). The mixture was kept overnight at 25 °C. LRX was dissolved in propylene glycol and added to the gel using a WiseStir HS-100D propeller stirrer (Daihan Scientifi c Co Ltd, Korea) at 50 rpm for 15 minutes.
Solubility study
Phosphate buff er solution (PBS) was used as a receptor phase in in vitro and ex vivo ex periments (4). Solubility of LRX was studied in pH 7.4. Fi een mL of pH 7.4 PBS was placed in four 25-mL fl asks. A quantity of LRX was placed in each fl ask, which was greater than the quantity expected to dissolve in the receptor phase. Flasks were tightly closed. All fl asks were placed in a water bath (WiseBath ® , DAIHAN Scientifi c Co. Ltd.) at 25 ± 1 o C. Apparatus was maintained under 200 rpm continuous agitation for 24 h. Dispersion was then fi ltered through S&S 5893 blue ribbon fi lter paper (Schleicher und Schüll, Germany). A measured portion of clear supernatant was removed and diluted. Solubility of LRX in the receptor phase was analysed at 376 nm (Shimadzu UV-1601 spectrophotometer, Japan).
Entrapment effi ciency (EE) and loading capacity (LC) of nanoparticles
EE and LC of nanoparticles were determined by analysing the concentration of free drug in dispersion medium (13, 14) . Nanoparticle dispersion was diluted with water at 
FTIR analysis
FTIR was used to determinate chemical interaction between LRX and other ingredients used in formulations (15) . For this purpose, nanoparticle dispersions (NLC1 and NLC2) were diluted with water at predetermined times. Dilutions were centrifuged at 11,148 × g for 40 min. Residues were separetely transferred to glass plates and kept at 50 o C overnight to eliminate the aqueous phase. Samples were then used for FTIR analysis.
Pure LRX and samples in the powder form were scanned over a wavenumber range of 4000 to 650 cm -1 at a resolution of 4 cm -1 in a Perkin Elmer 100 FTIR instrument (USA) equipped with the Perkin Elmer Spectrum Version 6.0.2 So ware. Sample was placed on the sample stage and always the same force (force gauge 100 N) was applied to ensure reproducible contact between the sample and crystal for scanning. The system was operating in the transmission mode.
DSC analysis
DSC was used to obtain information about the melting and crystallization behaviour of solid lipids in nanoparticles, polymorphism, crystal ordering and drug-lipid interactions (16) . This was carried out on pure drugs, pure lipids and nanoparticles (Table I) . Melting peaks and enthalpies were calculated using the DSC 204 F1 so ware. Crystalline state of the drug in formulations was demonstrated by calculating the crystallization index (CI, %) using the following equation (17):
where M s and M p are melting enthalpy in J g -1 of lipid nanoparticles and pure solid lipid, respectively. g represents solid lipid concentration (%) in nanoparticle dispersion.
Particle and droplet size measurements
Particle and droplet size distribution of placebo and drug loaded nanoparticles and NE was determined using a Mastersizer 2000 laser diff ractometer (LD) equipped with a Hydro 2000MU wet sample dispersion unit (Malvern Instruments Ltd, UK) (18, 19) . For this purpose, samples were diluted with water at given times and all measurements were performed in triplicate at 25 o C. Water with a refractive index of 1.33 was used as the measurement medium. Results were analysed as the volumetric distribution of particle size. D10, D50 and D90 values (D10, D50 and D90 are maximum particle diameters below which 10, 50 and 90 % of the sample volume exists, respectively), and profi les of particle size distribution were obtained. Measurements were performed according to the Mie theory, which allows transformation of the measured intensity distribution data to volume in particle size measurements by LD. Each value was the average of three measurements.
In vitro drug release
The amount of LRX released from formulations was determined using the dialysis bag diff usion technique (13, 20) . Dialysis bags (Spectra/Por ® Dialysis Membrane, MWCO: 3.500, Spectrum Laboratories Inc., USA) were kept in pH 7.4 PBS overnight before the experiment. Bags were fi lled with 0.5 g of the formulation and both ends were tightly tied. They were immersed into conical fl asks containing 200 mL pH 7.4 PBS each. Flasks were planted in a water bath adjusted to a constant temperature of 37 ± 0.5 o C. Experiments were carried out at a 60-rpm continuous agitation for 48 hours. Samples were taken at predetermined time intervals. Sink condition was provided. Drug release was determined spectrophotometrically at 376 nm a er proper dilution of samples. Cumulative amount of LRX in the release medium was plo ed as a function of time. Six replicates were conducted for each experiment.
Kinetic evaluation of release profi les was made using zero-order, fi rst-order and Higuchi square-root models, as described in Eqs. (2-4), respectively. Korsmeyer-Peppas equation was also taken into consideration for determination of the release mechanism (Eq. 5) (21, 22) .
where M t and M 0 are amounts of drug released in the release medium at time t and at t = 0, respectively, k 0 , k 1 and k H are release constants of the zero-order, fi rst-order and Higuchi square-root model, respectively, M t /M ∞ fractional release of the drug, k and n, kinetic constant and diff usional release exponent are indicative of the release mechanism.
HPLC analysis
Quantifi cation of LRX was performed on a Thermo Separation Products (USA) HPLC unit (controller SN 4000, pump P 4000, autosampler AS 3000, photodiode array detector UV 6000 LP). UV absorption of LRX in each sample was detected at 384 nm. Data acquisition was performed with the ChromQuest 5.0 so ware. Separations were provided using a Phenomenex C 18 -column (250 mm × 4.6 mm i.d., 5-µm particle size) with a guard column (4 mm × 3 mm i.d.) packed with the same material.
The isocratic mobile phase was a 60:40 (V/V) mixture of acetonitrile and potassium dihydrogen phosphate buff er (0.05 mol L -1 ) at a fl ow rate of 1 mL min -1 . The assays were performed at RT and the injection volume was 20 µL.
Stock standard solution of LRX was prepared in the concentration of 0.1 mg mL -1 using pH 7.4 PBS as a solvent. Working standard solution of LRX was prepared in the concentration of 10 µg mL -1 using the same solvent. To evaluate linearity under the selected conditions, drug determination was carried out at six concentrations in the mobile phase. The calibration curve was found linear over the concentration range of 6.25-500 ng mL -1 (R 2 = 0.9990). This method was developed and validated for this study. Limit of detection (LOD) and limit of quantifi cation (LOQ) were 0.18 and 0.56 ng mL -1 , respectively. For regression equation, relative standard deviations (RSD, %) of the slope and intercept were 0.1 and 0.2, respectively.
Drug penetration through excised rat skin
Eighteen male Wistar albino rats (150-200 g) were provided by DETAE, Istanbul University Institute for Experimental Medicine, Turkey. The animals were housed in plastic cages at constant temperature (22 ± 1 °C) and humidity (60 ± 1 %) under a 12-h light-dark cycle. They were given standard laboratory diet and tap water ad libitum. Rats were acclimatized to the laboratory at least 7 days prior to the experiments. The experimental protocol was approved by the Local Ethical Commi ee of Animal Experiments in the Experimental Medical Research Institute of Istanbul University, Turkey (2011/33). Rats were sacrifi ced by cervical dislocation and their skins were depilated. Full-thickness skin of Wistar albino rats were used to evaluate reservoir action potentials of lipid nanoparticles and permeation characteristics of LRX entrapped in lipid nanocarriers through the skin (4, 23, 24).
The dermal surface was carefully cleaned to remove subcutaneous tissues without damaging the epidermal surface. Underlying fa y tissue was removed by blunt dissection.
One g of the formulation was applied to the donor phase facing the surface of rat skins placed between two halves of Franz-type diff usion cells. Receptor phase was 33.2 mL pH 7.4 PBS. The study was performed for 48 hours at 37 ± 1 o C. Penetration of drugs was assayed by HPLC on samples collected at predetermined time intervals. Three replicates were executed for each experiment.
Analysis of release data
Statistical evaluations of data obtained from in vitro drug release and ex vivo drug penetration experiments were made by using the one-way ANOVA test in order to determine the diff erences between profi les. p < 0.05 was set as the level of signifi cance.
RESULTS AND DISCUSSION
Solubility of LRX and encapsulation parameters of nanoparticles
Solubility of LRX in pH 7.4 PBS was 0.303 ± 0.008 mg mL -1 . LRX was successfuly loaded into SLN and NLC based on Compritol ® 888 ATO, Lane e ® O and oleic acid (Table  II) . EE and LC were increased by addition of liquid lipid into the lipid phase, providing a more suitable medium for LRX to dissolve during the hot homogenization process, since drugs solubility is usually higher in liquid lipids compared to solid lipids. Liquid lipid also infl uences the crystallization behavior and crystal structure of solid lipid, i.e., it provides a special structure for be er drug accommodation in the nanoparticle (5). Crystallization of solid lipid in nanoparticles to its more stable state is prevented. Or, large distances between fa y acid chains and amorphous clusters occur in the nanoparticle structure. Thus, drug accommodation is provided in the structure of nanoparticles in the amorphous state, or containing amorphous clusters.
FTIR analysis
We extensively discussed the FTIR data of LRX in our previous report (4) . FTIR analysis indicated that drug and excipients were compatible at 4, 25 and 40 o C for 6 months (Fig. 1) .
Characteristic main bands of LRX displayed lower intensity and broader peaks caused by other ingredients. C=O stretching bands caused by the aliphatic ester structure of triglycerides displayed sharp peaks at 1736.05-1710.54 cm melting enthalpy (Fig. 2) . Placebo Compritol ® 888 ATO nanoparticles PSLN1 gave a broader melting peak at 74.29 o C with melting enthalpy of 15.45 J g -1 due to the addition of surfactant to the dispersion (25) . CI was calculated as 70.1 %. Decrease in the onset and peak temperatures obtained from nanoparticles could also be a ributed to the small size eff ect, explained by the Thomson equation (17) . Increased melting range compared to bulk lipids could be correlated with less ordered crystals or amorphous state. In this case, the melt of the substance requires less energy than a perfect crystalline substance, which needs to overcome the la ice force. It was thus concluded that lower melting enthalpy values compared to bulk solid lipids resulted in a lower ordered la ice arrangement and vice versa. Much less ordered arrangement in NLC formulations was a ributed to the existence of liquid lipid as a quest substance. Liquid lipid incorporation resulted in delayed crystallization of nanoparticles. 14.43 J g -1 (72. Lane e ® O gave a double peak at 43.26 and 55.95 o C, which could be a ributed to the mixture of cetyl alcohol and stearyl alcohol (Fig. 2) . In placebo SLN (PSLN2), peaks were broader and showed a tendency to be shi ed by the second peak in the case of drug incorporation (SLN2). NLC formulations (PNLC2 and NLC2) gave broader peaks. A er 6 months of storage, the crystallization behavior of nanoparticles based on Lane e ® O was slightly altered at 25 °C compared to the DSC curves obtained before storage (thermograms obtained for the formulation a er storage are not shown). 
DSC analysis
Particle and droplet size of nanoparticles and NE
LD analysis displayed narrow size distributions for nanoparticles and NEs (Table III) . Formulations were obtained in a range of 0.141 to 0.295 µm diameter (D50). SLN based on Compritol ® 888 ATO and Lane e ® O showed 0.185 and 0.295 µm particle size, whereas NLC displayed 0.185 and 0.266 µm particle size, respectively. Droplet size of NE was 0.166 µm. It was observed that addition of liquid oil into the lipophilic phase resulted in a decrease in particle size while drug incorporation did not cause any signifi cant change. As a consequence, NEs had the lowest droplet size, as expected. Smaller particle and droplet size of NLC and NE formulations compared to SLN formulations can be a ributed to the fact that lower viscosity of the lipophilic phase resulted in a decrease in size during the hot homogenization process. Values from particle and droplet size measurements of formulations at production date (PD) and a er storage at 4, 25 and 40 °C for 6 months.
In general, particle size of SLN1 and NLC1 based on Compritol ® 888 ATO did not signifi cantly alter at various temperatures over 6 months, indicating good physical stability. However, SLN2 and NLC2 based on Lane e ® O displayed slight agglomeration a er 6 months. Droplet size of NE ranged between 0.168 and 0.205 µm under all conditions during 6 months.
In vitro drug release
Controlled drug release was observed for all nanoformulations. LRX gel gave the fastest drug release: 100 % for 24 hours (p < 0.05), followed by 97.7, 73.7, 64.2, 54.6 and 49.2 % for NE, NLC2, NLC1, SLN2 and SLN1, respectively, a er 48 hours (Fig. 3) . NLC formulations displayed higher release rates compared to SLN formulations containing the same solid lipids (SLN1 vs. NLC1, p < 0.05 and SLN2 vs. NLC2, p < 0.05). Although a non-signifi cant diff erence was observed between formulations SLN2 and NLC1, the release rate of LRX increased with a decrease in CI and crystalline state of nanoparticles in general. Addition of liquid lipids provided easier drug diff usion. Addition of liquid lipid to SLN based on Lane e ® O (NLC2) revealed more imperfections. Table IV indicates that drug release from SLN1, SLN2 and NE met the Higuchi and Korsmeyer-Peppas models whereas NLC1 and NLC2 displayed drug release according to the the Korsmeyer-Peppas model. Higuchi matrix kinetics was strictly dominant for LRX release from the gel. Release exponent of the Korsmeyer-Peppas model (n) was obtained to characterize the drug release mechanism from nanoparticles and Fickian diff usion release (case I diff usional) was determined (0.5 < n) (21, 22) . Case I diff usional transport was thought to be valid here, indicating basic drug diff usion from nanoparticles and NE. The release medium did not enter into nanoparticles and drug release was independent of water penetration into the matrix (26) . It was concluded that data obtained from the in vitro release study explained the solid solution model of LRX encapsulation of SLN1 and SLN2. 29.76 and 31.29 % of the drug were released from nanoparticles and drug release reached 49.21 and 54.59 % a er 48 hours, respectively. Burst release of the drug was controversial here. Korsmeyer-Peppas calculation also indicated the Higuchi square-root model drug release, giving the highest R values among zero-order and fi rst-order drug release models. NLC1 and NLC2 were thought to contribute to amorphous or imperfect types of the drug encapsulation model under consideration of the in vitro release study and kinetic evaluation. Thermal behaviours of nanoparticles displayed by DSC experiments supported our thesis. ) (Fig. 4) . However, statistically similar penetration profi les were obtained with SLN2, NLC1 and NLC2. The steady-state fl ux that drug penetration reached diff ered for each formulation. It was observed between 6 and 48 hours for SLN1, NLC1 and NLC2, 6 and 24 hours for SLN2, and between 3 and 12 hours for NE. LRX gel displayed a steady-state fl ux between 6 and 24 hours. In those periods, penetration rates were 1.073, 1.857, 1.262, 1.342, 4.746 and 0.326 µg cm -2 h -1 for SLN1, SLN2, NLC1, NLC2, NE and LRX gel, respectively. Liquid lipid composition of droplets and lower droplet size of NE (0.166 µm, D50), compared to the particle size of SLN1 (0.185 µm) and NLC1 (0.185 µm) based on Compritol ® 888 ATO, and SLN2 (0.295 µm) and NLC2 (0.266 µm) based on Lane e ® O, resulted in the highest LRX penetration rate. Additionally, NE spoiled the lipid organisation in the deeper horny layer and thus increased skin penetration of the drug. In the case of SLN and NLC, spontaneous occlusivity contributed to the penetration properties through the skin due to the particle size of formulations in the nanometer range. Subsequent skin hydration promoted drug penetration (7, 9, 27) . Particle size of SLN and NLC in the nanometer range led to their transfer into deeper skin layers. Nanoparticles then displayed reservoir action and sustained drug release through their pysicochemical properties such as high lipophilicity and solid state at body temperature. As a result, nanoparticles were found to release the drug as a consequence of polymorphic transitions in the solid lipid while penetrating across the skin. CONCLUSIONS SLN, NLC and NE of LRX were successfuly prepared with a high drug payload using Compritol ® 888 ATO, Lane e ® O and oleic acid as solid and liquid lipids. Stability experiments displayed that they were physically stable and drug-excipient compatibility was available during 6 months of storage. They increased the skin penetration rate of the drug for 3-4 times compared to a traditional LRX gel formulation, acting as a depot to provide sustained drug release in the skin. As a result, SLN, NLC and NE of LRX were concluded to off er benefi ts for the treatment of infl ammatory and painful conditions via topical application while decreasing side-eff ects of the drug caused by oral administration.
